Analysts think CTSO stock price could increase by 524%
Nov 27, 2024, 12:26 PM
0.08%
What does CTSO do
CytoSorbents, headquartered in Princeton, New Jersey, specializes in blood purification technology and critical care immunotherapy, employing 186 people since its IPO on June 17, 2005. Its flagship product, CytoSorb, addresses cytokine storms in critical illnesses, with additional products like VetResQ and various candidates under development.
4 analysts think CTSO stock price will increase by 523.82%. The current median analyst target is $5.61 compared to a current stock price of $0.90. The lowest analysts target is $1.01 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
